Targeting vasoactive peptides for managing calcific aortic valve disease

References

• Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2438–88.
   PubMed Web of Science ®Google Scholar
• Otto CM, Prendergast B. Aortic-valve stenosis-from patients at risk to severe valve obstruction. N Engl J Med. 2014;371:744–56.
   PubMed Web of Science ®Google Scholar
• Jander N, Minners J, Holme I, Gerdts E, Boman K, Brudi P, et al. Outcome of patients with low-gradient severe aortic stenosis and preserved ejection fraction. Circulation. 2011;123:887–95.
   PubMed Web of Science ®Google Scholar
• Aronow WS. Valvular aortic stenosis in the elderly. Cardiol Rev. 2007;15:217–25.
   PubMedGoogle Scholar
• Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation. 1994;90:844–53.
   PubMed Web of Science ®Google Scholar
• Rosenhek R, Zilberszac R, Schemper M, Czerny M, Mundigler G, Graf S, et al. Natural history of very severe aortic stenosis. Circulation. 2010;121:151–6.
   PubMed Web of Science ®Google Scholar
• Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol. 2012;60:1854–63.
   PubMed Web of Science ®Google Scholar
• Qian J, Chen Z, Ge J, Ma J, Chang S, Fan B, et al. Relationship between aortic valve calcification and the severity of coronary atherosclerotic disease. J Heart Valve Dis. 2010;194:466–70.
   Google Scholar
• Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol. 2013;216:R1–17.
   PubMed Web of Science ®Google Scholar
• Rossi GP, Sacchetto A, Cesari M, Pessina AC. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res. 1999;43:300–7.
   PubMed Web of Science ®Google Scholar
• Unger T, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, et al. Angiotensin receptors. J Hypertens Suppl. 1996;14:S95–S103.
   PubMedGoogle Scholar
• Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52:11–34.
   PubMed Web of Science ®Google Scholar
• Steckelings UM, Paulis L, Namsolleck P, Unger T. AT2 receptor agonists: hypertension and beyond. Curr Opin Nephrol Hypertens. 2012;21:142–6.
   PubMed Web of Science ®Google Scholar
• O'Brien KD, Shavelle DM, Caulfield MT, McDonald TO, Olin-Lewis K, Otto CM, et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation. 2002;106:2224–30.
   PubMed Web of Science ®Google Scholar
• Helske S, Lindstedt KA, Laine M, Mayranpaa M, Werkkala K, Lommi J, et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol. 2004;44:1859–66.
   PubMed Web of Science ®Google Scholar
• Peltonen T, Napankangas J, Vuolteenaho O, Ohtonen P, Soini Y, Juvonen T, et al. Apelin and its receptor APJ in human aortic valve stenosis. J Heart Valve Dis. 2009;18:644–52.
   PubMed Web of Science ®Google Scholar
• Peltonen T, Napankangas J, Ohtonen P, Aro J, Peltonen J, Soini Y, et al. (Pro)renin receptors and angiotensin converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in human aortic valve stenosis. Atherosclerosis. 2011;216:35–43.
   PubMed Web of Science ®Google Scholar
• Fujisaka T, Hoshiga M, Hotchi J, Takeda Y, Jin D, Takai S, et al. Angiotensin II promotes aortic valve thickening independent of elevated blood pressure in apolipoprotein-E deficient mice. Atherosclerosis. 2013;226:82–7.
   PubMed Web of Science ®Google Scholar
• Osako MK, Nakagami H, Shimamura M, Koriyama H, Nakagami F, Shimizu H, et al. Cross-talk of receptor activator of nuclear factor-κB ligand signaling with renin-angiotensin system in vascular calcification. Arterioscler Thromb Vasc Biol. 2013;33:1287–96.
   PubMed Web of Science ®Google Scholar
• Ndip A, Wilkinson FL, Jude EB, Boulton AJ, Alexander MY. RANKL-OPG and RAGE modulation in vascular calcification and diabetes: novel targets for therapy. Diabetologia. 2014;57:2251–60.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Yamamoto H, Yoshida K, Kisanuki A, Hirano Y, Ohte N, et al. Prognostic factors for progression of early- and late-stage calcific aortic valve disease in Japanese: the Japanese Aortic Stenosis Study (JASS) Retrospective Analysis. Hypertens Res. 2010;33:269–74.
   PubMed Web of Science ®Google Scholar
• Capoulade R, Clavel MA, Mathieu P, Cote N, Dumesnil JG, Arsenault M, et al. Impact of hypertension and renin-angiotensin system inhibitors in aortic stenosis. Eur J Clin Invest. 2013;43:1262–72.
   PubMed Web of Science ®Google Scholar
• Cote N, Couture C, Pibarot P, Despres JP, Mathieu P. Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves. Eur J Clin Invest. 2011;41:1172–9.
   PubMed Web of Science ®Google Scholar
• Helske-Suihko S, Laine M, Lommi J, Kaartinen M, Werkkala K, Kovanen PT, et al. Is blockade of the Renin-Angiotensin system able to reverse the structural and functional remodeling of the left ventricle in severe aortic stenosis? J Cardiovasc Pharmacol. 2015;65:233–40.
   PubMed Web of Science ®Google Scholar
• Arishiro K, Hoshiga M, Negoro N, Jin D, Takai S, Miyazaki M, et al. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol. 2007;49:1482–9.
   PubMed Web of Science ®Google Scholar
• Chockalingam A, Venkatesan S, Subramaniam T, Jagannathan V, Elangovan S, Alagesan R, et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: symptomatic cardiac obstruction-pilot study of enalapril in aortic stenosis (SCOPE-AS). Am Heart J. 2004;147:E19.
   PubMed Web of Science ®Google Scholar
• Jimenez-Candil J, Bermejo J, Yotti R, Cortina C, Moreno M, Cantalapiedra JL, et al. Effects of angiotensin converting enzyme inhibitors in hypertensive patients with aortic valve stenosis: a drug withdrawal study. Heart. 2005;91:1311–18.
   PubMed Web of Science ®Google Scholar
• Dalsgaard M, Iversen K, Kjaergaard J, Grande P, Goetze JP, Clemmensen P, et al. Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in patients with severe aortic stenosis: a placebo-controlled, randomized study. Am Heart J. 2014;167:226–34.
   PubMed Web of Science ®Google Scholar
• Bull S, Loudon M, Francis JM, Joseph J, Gerry S, Karamitsos TD, et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor ramipril in aortic stenosis (RIAS trial). Eur Heart J Cardiovasc Imaging. 2015;16:834–41.
   PubMed Web of Science ®Google Scholar
• Helske S, Syvaranta S, Kupari M, Lappalainen J, Laine M, Lommi J, et al. Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. Eur Heart J. 2006;27:1495–504.
   PubMed Web of Science ®Google Scholar
• Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86:747–803.
   PubMed Web of Science ®Google Scholar
• Machado RD, Santos RA, Andrade SP. Mechanisms of angiotensin-(1-7)-induced inhibition of angiogenesis. Am J Physiol Regul Integr Comp Physiol. 2001;280:R994–R1000.
   PubMedGoogle Scholar
• Fox KM. European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;3629386:782–8.
   Google Scholar
• Elder DH, McAlpine-Scott V, Choy AM, Struthers AD, Lang CC. Aortic valvular heart disease: is there a place for angiotensin-converting-enzyme inhibitors? Expert Rev Cardiovasc Ther. 2013;11:107–14.
   PubMedGoogle Scholar
• O'Brien KD, Probstfield JL, Caulfield MT, Nasir K, Takasu J, Shavelle DM, et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med. 2005;165:858–62.
   PubMedGoogle Scholar
• Nadir MA, Wei L, Elder DH, Libianto R, Lim TK, Pauriah M, et al. Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. J Am Coll Cardiol. 2011;58:570–6.
   PubMed Web of Science ®Google Scholar
• Lindman BR, Bonow RO, Otto CM. Current management of calcific aortic stenosis. Circ Res. 2013;113:223–37.
   PubMed Web of Science ®Google Scholar
• Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651–7.
   PubMed Web of Science ®Google Scholar
• Ngo DT, Stafford I, Sverdlov AL, Qi W, Wuttke RD, Zhang Y, et al. Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. Br J Pharmacol. 2011;162:722–32.
   PubMed Web of Science ®Google Scholar
• Alenina N, Xu P, Rentzsch B, Patkin EL, Bader M. Genetically altered animal models for Mas and angiotensin-(1-7). Exp Physiol. 2008;93:528–37.
   PubMed Web of Science ®Google Scholar
• Vaajanen A, Kalesnykas G, Vapaatalo H, Uusitalo H. The expression of mas-receptor of the renin-angiotensin system in the human eye. Graefes Arch Clin Exp Ophthalmol. 2015;253:1053–9.
   PubMed Web of Science ®Google Scholar
• Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995–6008.
   PubMed Web of Science ®Google Scholar
• Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109:1417–27.
   PubMed Web of Science ®Google Scholar
• Satofuka S, Ichihara A, Nagai N, Noda K, Ozawa Y, Fukamizu A, et al. (Pro)renin receptor promotes choroidal neovascularization by activating its signal transduction and tissue renin-angiotensin system. Am J Pathol. 2008;173:1911–8.
   PubMed Web of Science ®Google Scholar
• Uraoka M, Ikeda K, Nakagawa Y, Koide M, Akakabe Y, Nakano-Kurimoto R, et al. Prorenin induces ERK activation in endothelial cells to enhance neovascularization independently of the renin-angiotensin system. Biochem Biophys Res Commun. 2009;390:1202–7.
   PubMed Web of Science ®Google Scholar
• Cruciat CM, Ohkawara B, Acebron SP, Karaulanov E, Reinhard C, Ingelfinger D, et al. Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling. Science. 2010;327:459–63.
   PubMed Web of Science ®Google Scholar
• Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation. 2005;112:I229–34. 9:
   PubMed Web of Science ®Google Scholar
• Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107:513–23.
   PubMed Web of Science ®Google Scholar
• McAllister BS, Leeb-Lundberg F, Olson MS. Bradykinin inhibition of EGF- and PDGF-induced DNA synthesis in human fibroblasts. Am J Physiol. 1993;265:C477–84.
   PubMedGoogle Scholar
• Helske S, Laine M, Kupari M, Lommi J, Turto H, Nurmi L, et al. Increased expression of profibrotic neutral endopeptidase and bradykinin type 1 receptors in stenotic aortic valves. Eur Heart J. 2007;28:1894–903.
   PubMed Web of Science ®Google Scholar
• Ferrario CM. New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension. 2010;55:445–52.
   PubMed Web of Science ®Google Scholar
• Morissette G, Houle S, Gera L, Stewart JM, Marceau F. Antagonist, partial agonist and antiproliferative actions of B-9870 (CU201) as a function of the expression and density of the bradykinin B1 and B2 receptors. Br J Pharmacol. 2007;150:369–79.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Sharma K, Kumar N, Roy P. Bradykinin regulates osteoblast differentiation by Akt/ERK/NFκB signaling axis. J Cell Physiol. 2014;229:2088–105.
   PubMed Web of Science ®Google Scholar
• Barton M, Traupe T, Haudenschild CC. Endothelin, hypercholesterolemia and atherosclerosis. Coron Artery Dis. 2003;14:477–90.
   PubMed Web of Science ®Google Scholar
• Peltonen T, Taskinen P, Napankangas J, Leskinen H, Ohtonen P, Soini Y, et al. Increase in tissue endothelin-1 and ETA receptor levels in human aortic valve stenosis. Eur Heart J. 2009;30:242–9.
   PubMed Web of Science ®Google Scholar
• Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Gabriel H, Binder T, et al. Big endothelin-1 is not a predictor in aortic stenosis, but is related to arterial blood pressure. Int J Cardiol. 2006;113:174–80.
   PubMed Web of Science ®Google Scholar
• Bohm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res. 2007;76:8–18.
   PubMed Web of Science ®Google Scholar
• Wu SY, Zhang BH, Pan CS, Jiang HF, Pang YZ, Tang CS, et al. Endothelin-1 is a potent regulator in vivo in vascular calcification and in vitro in calcification of vascular smooth muscle cells. Peptides. 2003;24:1149–56.
   PubMed Web of Science ®Google Scholar
• Norman PE, Powell JT. Vitamin D and cardiovascular disease. Circ Res. 2014;114:379–93.
   PubMed Web of Science ®Google Scholar
• Schmidt N, Brandsch C, Kühne H, Thiele A, Hirche F, Stangl GI. Vitamin D receptor deficiency and low vitamin D diet stimulate aortic calcification and osteogenic key factor expression in mice. PLoS One. 2012;7:e35316.
   PubMed Web of Science ®Google Scholar
• Leskelä HV, Vuolteenaho O, Koivula MK, Taskinen P, Ruskoaho H, Peltonen T, et al. Tezosentan inhibits uptake of proinflammatory endothelin-1 in stenotic aortic valves. J Heart Valve Dis. 2012;211:23–30.
   Google Scholar
• Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:347–54.
   PubMed Web of Science ®Google Scholar
• Yu XH, Tang ZB, Liu LJ, Qian H, Tang SL, Zhang DW, et al. Apelin and its receptor APJ in cardiovascular diseases. Clin Chim Acta. 2014;428:1–8.
   PubMed Web of Science ®Google Scholar
• Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277:14838–43.
   PubMed Web of Science ®Google Scholar
• Sun X, Iida S, Yoshikawa A, Senbonmatsu R, Imanaka K, Maruyama K, et al. Non-activated APJ suppresses the angiotensin II type 1 receptor, whereas apelin-activated APJ acts conversely. Hypertens Res. 2011;34:701–6.
   PubMed Web of Science ®Google Scholar
• Saint-Geniez M, Masri B, Malecaze F, Knibiehler B, Audigier Y. Expression of the murine msr/apj receptor and its ligand apelin is upregulated during formation of the retinal vessels. Mech Dev. 2002;110:183–6.
   PubMed Web of Science ®Google Scholar
• Goidescu CM, Vida-Simiti LA. The apelin-APJ system in the evolution of heart failure. Clujul Med. 2015;88:3–8.
   PubMedGoogle Scholar
• Cox CM, D'Agostino SL, Miller MK, Heimark RL, Krieg PA. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol. 2006;296:177–89.
   PubMed Web of Science ®Google Scholar
• Helske S, Oksjoki R, Lindstedt KA, Lommi J, Turto H, Werkkala K, et al. Complement system is activated in stenotic aortic valves. Atherosclerosis. 2008;196:190–200.
   PubMed Web of Science ®Google Scholar
• Eyries M, Siegfried G, Ciumas M, Montagne K, Agrapart M, Lebrin F, et al. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ Res. 2008;103:432–40.
   PubMed Web of Science ®Google Scholar
• Yuan ZS, Zhou YZ, Liao XB, Luo JW, Shen KJ, Hu YR, et al. Apelin attenuates the osteoblastic differentiation of aortic valve interstitial cells via the ERK and PI3-K/Akt pathways. Amino Acids. 2015;47:2475–82.
   PubMed Web of Science ®Google Scholar
• Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest. 2008;118:3343–54.
   PubMed Web of Science ®Google Scholar
• Pchejetski D, Foussal C, Alfarano C, Lairez O, Calise D, Guilbeau-Frugier C, et al. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J. 2012;33:2360–9.
   PubMed Web of Science ®Google Scholar
• Nagpal V, Rai R, Place AT, Murphy SB, Verma SK, Ghosh AK, et al. MiR-125b is critical for fibroblast-to-myofibroblast transition and cardiac fibrosis. Circulation. 2016;1333:291–301.
   Google Scholar
• Ohukainen P, Syvaranta S, Napankangas J, Rajamaki K, Taskinen P, Peltonen T, et al. MicroRNA-125b and chemokine CCL4 expression are associated with calcific aortic valve disease. Ann Med. 2015;47:423–9.
   PubMed Web of Science ®Google Scholar
• Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA. 2000;97:8525–9.
   PubMed Web of Science ®Google Scholar
• Wu C, Wu F, Pan J, Morser J, Wu Q. Furin-mediated processing of Pro-C-type natriuretic peptide. J Biol Chem. 2003;278:25847–52.
   PubMed Web of Science ®Google Scholar
• Peltonen TO, Taskinen P, Soini Y, Rysa J, Ronkainen J, Ohtonen P, et al. Distinct downregulation of C-type natriuretic peptide system in human aortic valve stenosis. Circulation. 2007;116:1283–9.
   PubMed Web of Science ®Google Scholar
• Chusho H, Tamura N, Ogawa Y, Yasoda A, Suda M, Miyazawa T, et al. Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci USA. 2001;98:4016–21.
   PubMed Web of Science ®Google Scholar
• Komatsu Y, Chusho H, Tamura N, Yasoda A, Miyazawa T, Suda M, et al. Significance of C-type natriuretic peptide (CNP) in endochondral ossification: analysis of CNP knockout mice. J Bone Miner Metab. 2002;20:331–6.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Zhang J, Cai Y, Zhou YB, Wen GB, Tang CS, et al. C-type natriuretic peptide inhibiting vascular calcification might involve decreasing bone morphogenic protein 2 and osteopontin levels. Mol Cell Biochem. 2014;392:65–76.
   PubMed Web of Science ®Google Scholar
• Kimura T, Nojiri T, Hino J, Hosoda H, Miura K, Shintani Y, et al. C-type natriuretic peptide ameliorates pulmonary fibrosis by acting on lung fibroblasts in mice. Respir Res. 2016;17:19
   PubMed Web of Science ®Google Scholar
• Qian JY, Haruno A, Asada Y, Nishida T, Saito Y, Matsuda T, et al. Local expression of C-type natriuretic peptide suppresses inflammation, eliminates shear stress-induced thrombosis, and prevents neointima formation through enhanced nitric oxide production in rabbit injured carotid arteries. Circ Res. 2002;91:1063–9.
   PubMed Web of Science ®Google Scholar
• Yip CY, Blaser MC, Mirzaei Z, Zhong X, Simmons CA. Inhibition of pathological differentiation of valvular interstitial cells by C-type natriuretic peptide. Arterioscler Thromb Vasc Biol. 2011;31:1881–9.
   PubMed Web of Science ®Google Scholar
• Moyes AJ, Khambata RS, Villar I, Bubb KJ, Baliga RS, Lumsden NG, et al. Endothelial C-type natriuretic peptide maintains vascular homeostasis. J Clin Invest. 2014;124:4039–51.
   PubMed Web of Science ®Google Scholar
• Krejci P, Masri B, Fontaine V, Mekikian PB, Weis M, Prats H, et al. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J Cell Sci. 2005;118:5089–100.
   PubMed Web of Science ®Google Scholar
• Satta J, Oiva J, Salo T, Eriksen H, Ohtonen P, Biancari F, et al. Evidence for an altered balance between matrix metalloproteinase-9 and its inhibitors in calcific aortic stenosis. Ann Thorac Surg. 2003;76:681–8.
   PubMed Web of Science ®Google Scholar
• Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation. 2016;13311:1115–24.
   Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
   PubMed Web of Science ®Google Scholar
• Steadman CD, Ray S, Ng LL, McCann GP. Natriuretic peptides in common valvular heart disease. J Am Coll Cardiol. 2010;55:2034–48.
   PubMed Web of Science ®Google Scholar
• Cimadevilla C, Cueff C, Hekimian G, Dehoux M, Lepage L, Iung B, et al. Prognostic value of B-type natriuretic peptide in elderly patients with aortic valve stenosis: the COFRASA-GENERAC study. Heart. 2013;99:461–7.
   PubMed Web of Science ®Google Scholar
• Clavel MA, Malouf J, Michelena HI, Suri RM, Jaffe AS, Mahoney DW, et al. B-type natriuretic peptide clinical activation in aortic stenosis: impact on long-term survival. J Am Coll Cardiol. 2014;63:2016–25.
   PubMed Web of Science ®Google Scholar
• Vahanian A, Alfieri O, Andreotti F Antunes MJ, et al. Joint task force on the management of valvular heart disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;3319:2451–96.
   Google Scholar
• Peltonen T, Ohtonen P, Näpänkangas J, Ohukainen P, Ruskoaho H, Taskinen P. Statin treatment and gene expression of anti-atherogenic factor C-type natriuretic peptide system in stenotic aortic valves. J Heart Valve Dis. 2011;205:545–51.
   Google Scholar